Cytokine storm syndrome in SARS-CoV-2: a review
-
Braira Wahid
,
Noshaba Rani
Abstract
After wreaking havoc on a global level with a total of 5,488,825 confirmed cases and 349,095 deaths as of May 2020, severe acute respiratory syndrome coronavirus 2 is truly living up to the expectations of a 21st-century pandemic. Since the major cause of mortality is a respiratory failure from acute respiratory distress syndrome, the only present-day management option is supportive as the transmission relies solely on human-to-human contact. Patients suffering from coronavirus disease 2019 (COVID-19) should be tested for hyper inflammation to screen those for whom immunosuppression can increases chances of survival. As more and more clinical data surfaces, it suggests patients with mild or severe cytokine storms are at greater risk of failing fatally and hence these cytokine storms should be targets for treatment in salvaging COVID-19 patients.
-
Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.
-
Research funding: None declared.
-
Conflict of interest statement: None declared.
References
1. Saghazadeh, A, Rezaei, N. Towards treatment planning of COVID-19: rationale and hypothesis for the use of multiple immunosuppressive agents: anti-antibodies, immunoglobulins, and corticosteroids. Int Immunopharm 2020;84:106560. https://doi.org/10.1016/j.intimp.2020.106560.Search in Google Scholar
2. Wang, W, Tang, J, Wei, F. Updated understanding of the outbreak of 2019 novel coronavirus (2019‐nCoV) in Wuhan, China. J Med Virol 2020;92:441–7. https://doi.org/10.1002/jmv.25689.Search in Google Scholar
3. Wang, D, Hu, B, Hu, C, Zhu, F, Liu, X, Zhang, J, et al.. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. Jama 2020;323:1061–9. https://doi.org/10.1001/jama.2020.1585.Search in Google Scholar
4. Huang, C, Wang, Y, Li, X, Ren, L, Zhao, J, Hu, Y, et al.. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:497–506. https://doi.org/10.1016/s0140-6736(20)30183-5.Search in Google Scholar
5. Lei, J, Li, J, Li, X, Qi, X. CT imaging of the 2019 novel coronavirus (2019-nCoV) pneumonia. Radiology 2020;295:18. https://doi.org/10.1148/radiol.2020200236.Search in Google Scholar PubMed PubMed Central
6. Rothan, HA, Byrareddy, SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autoimmun 2020;109:102433. https://doi.org/10.1016/j.jaut.2020.102433.Search in Google Scholar PubMed PubMed Central
7. Perlman, S. Another decade, another coronavirus. N Engl J Med 2020;382:760–2.10.1056/NEJMe2001126Search in Google Scholar PubMed PubMed Central
8. Wu, F, Zhao, S, Yu, B, Chen, Y, Wang, W, Hu, Y, et al.. A new coronavirus associated with human respiratory disease in China. Nature 2020;579:265–9.10.1038/s41586-020-2008-3Search in Google Scholar PubMed PubMed Central
9. Zhou, P, Yang, X, Wang, X, Hu, B, Zhang, L, Zhang, W, et al.. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020;579:270–3.10.1038/s41586-020-2012-7Search in Google Scholar PubMed PubMed Central
10. Lillie, PJ, Samson, A, Li, A, Adams, K, Capstick, R, Barlow, GD, et al.. Novel coronavirus disease (Covid-19): the first two patients in the UK with person to person transmission. J Infect 2020;80:578–606. https://doi.org/10.1016/j.jinf.2020.02.020.Search in Google Scholar PubMed PubMed Central
11. Levy, M, Fink, M, Marshall, JC, Abraham, E, Angus, D, Cook, D, et al.. 2001 SCCM/ESICM/ACCP/ATS/SIS international sepsis definitions conference. Crit Care Med 2003;31:1250–6. https://doi.org/10.1097/01.ccm.0000050454.01978.3b.Search in Google Scholar
12. Tisoncik, JR, Korth, MJ, Simmons, CP, Farrar, J, Martin, TR, Katze, MG. Into the eye of the cytokine storm. Microbiol Mol Biol Rev 2012;76:16–32. https://doi.org/10.1128/mmbr.05015-11.Search in Google Scholar
13. Xu, Z, Shi, L, Wang, Y, Zhang, J, Huang, L, Zhang, C, et al.. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med 2020;8:420–2. https://doi.org/10.1016/s2213-2600(20)30076-x.Search in Google Scholar
14. Hussman, JP. Cellular and molecular pathways of COVID-19 and potential points of therapeutic intervention. Front Pharmacol 2020;11:1169. https://doi.org/10.3389/fphar.2020.01169.Search in Google Scholar PubMed PubMed Central
15. Zhou, Y, Fu, B, Zheng, X, Wang, D, Zhao, C, Qi, Y, et al.. Pathogenic T cells and inflammatory monocytes incite inflammatory storm in severe COVID-19 patients. Natl Sci Rev 2020;7:998–1002.10.1093/nsr/nwaa041Search in Google Scholar PubMed PubMed Central
16. Zuo, Y, Zuo, M, Yalavarthi, S, Gockman, K, Madison, JA, Shi, H, et al.. Neutrophil extracellular traps and thrombosis in COVID-19. J Thromb Thrombolysis 2021;51:446–53. https://doi.org/10.1007/s11239-020-02324-z.Search in Google Scholar PubMed PubMed Central
17. Barnes, BJ, Adrover, JM, Baxter-Stoltzfus, A, Borczuk, A, Cools-Lartigue, J, Crawford, JM, et al.. Targeting potential drivers of COVID-19: neutrophil extracellular traps. J Exp Med 2020;217:652–7. https://doi.org/10.1084/jem.20200652.Search in Google Scholar PubMed PubMed Central
18. Hirano, T, Murakami, M. COVID-19: a new virus, but a familiar receptor and cytokine release syndrome. Immunity 2020;52:731–3. https://doi.org/10.1016/j.immuni.2020.04.003.Search in Google Scholar PubMed PubMed Central
19. Cheng, J, Huang, C, Zhang, GJ, Liu, DW, Li, P, Lu, CY, et al.. Epidemiological characteristics of novel coronavirus pneumonia in Henan. Chin J Tuberc Respir Dis 2020;43:E027. https://doi.org/10.3760/cma.j.cn112147-20200222-00148.Search in Google Scholar PubMed
20. Ye, Q, Wang, B, Mao, J. The pathogenesis and treatment of the Cytokine Storm in COVID-19. J Infect 2020;80:607–13.10.1016/j.jinf.2020.03.037Search in Google Scholar PubMed PubMed Central
21. Shimabukuro-Vornhagen, A, Gödel, P, Subklewe, M, Stemmler, HJ, Schlößer, HA, Schlaak, M, et al.. Cytokine release syndrome. J Immunother Canc 2018;6:56. https://doi.org/10.1186/s40425-018-0343-9.Search in Google Scholar
22. Hu, B, Huang, S, Yin, L. The cytokine storm and COVID‐19. J Med Virol 2021;93:250–6. https://doi.org/10.1002/jmv.26232.Search in Google Scholar
23. Liu, J, Li, S, Liu, J, Liang, B, Wang, X, Wang, H, et al.. Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients. EBioMedicine 2020;55:102763. https://doi.org/10.1016/j.ebiom.2020.102763.Search in Google Scholar
24. Mehta, P, McAuley, DF, Brown, M, Sanchez, E, Tattersall, RS, Manson, JJ. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 2020;395:1033–4. https://doi.org/10.1016/s0140-6736(20)30628-0.Search in Google Scholar
25. Law, HK, Cheung, CY, Ng, HY, Sia, SF, Chan, YO, Luk, W, et al.. Chemokine up-regulation in sars-coronavirus–infected, monocyte-derived human dendritic cells. Blood 2005;106:2366–74. https://doi.org/10.1182/blood-2004-10-4166.Search in Google Scholar PubMed PubMed Central
26. Cheung, CY, Poon, LLM, Ng, IHY, Luk, W, Sia, S-F, Wu, MHS, et al.. Cytokine responses in severe acute respiratory syndrome coronavirus-infected macrophages in vitro: possible relevance to pathogenesis. J Virol 2005;79:7819–26. https://doi.org/10.1128/jvi.79.12.7819-7826.2005.Search in Google Scholar PubMed PubMed Central
27. Lau, SK, Lau, CCY, Chan, K-H, Li, CPY, Chen, H, Jin, D-Y, et al.. Delayed induction of proinflammatory cytokines and suppression of innate antiviral response by the novel Middle East respiratory syndrome coronavirus: implications for pathogenesis and treatment. J Gen Virol 2013;94:2679–90. https://doi.org/10.1099/vir.0.055533-0.Search in Google Scholar PubMed
28. Tynell, J, Westenius, V, Rönkkö, E, Munster, VJ, Melén, K, Österlund, P, et al.. Middle East respiratory syndrome coronavirus shows poor replication but significant induction of antiviral responses in human monocyte-derived macrophages and dendritic cells. J Gen Virol 2016;97:344. https://doi.org/10.1099/jgv.0.000351.Search in Google Scholar PubMed PubMed Central
29. Zhou, J, Chu, H, Li, C, Wong, BH-Y, Cheng, Z-S, Poon, VK-M, et al.. Active replication of Middle East respiratory syndrome coronavirus and aberrant induction of inflammatory cytokines and chemokines in human macrophages: implications for pathogenesis. J Infect Dis 2014;209:1331–42. https://doi.org/10.1093/infdis/jit504.Search in Google Scholar PubMed PubMed Central
30. Scheuplein, VA, Seifried, J, Malczyk, AH, Miller, L, Höcker, L, Vergara-Alert, J, et al.. High secretion of interferons by human plasmacytoid dendritic cells upon recognition of Middle East respiratory syndrome coronavirus. J Virol 2015;89:3859–69. https://doi.org/10.1128/jvi.03607-14.Search in Google Scholar PubMed PubMed Central
31. Chen, C, Zhang, XR, Ju, ZY, He, WF. Advances in the research of cytokine storm mechanism induced by Corona Virus Disease 2019 and the corresponding immunotherapies. Chin J Burns 2020;36:E005.Search in Google Scholar
32. Tanaka, T, Narazaki, M, Kishimoto, T. Immunotherapeutic implications of IL-6 blockade for cytokine storm. Immunotherapy 2016;8:959–70. https://doi.org/10.2217/imt-2016-0020.Search in Google Scholar
33. Wu, D, Yang, XO. TH17 responses in cytokine storm of COVID-19: an emerging target of JAK2 inhibitor Fedratinib. J Microbiol Immunol Infect 2020;53:368–70. https://doi.org/10.1016/j.jmii.2020.03.005.Search in Google Scholar
34. Zhang, C, Wu, Z, Li, J-W, Zhao, H, Wang, G-Q. Cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality. Int J Antimicrob Agents 2020;55:105954. https://doi.org/10.1016/j.ijantimicag.2020.105954.Search in Google Scholar
35. Mendoza, VMM. Interleukin-17: a potential therapeutic target in COVID-19. J Infect 2020;81:e136–8. https://doi.org/10.1016/j.jinf.2020.05.072.Search in Google Scholar
36. Luo, P, Liu, Y, Qui, L, Liu, X, Liu, D, Li, J. Tocilizumab treatment in COVID‐19: a single center experience. J Med Virol 2020;92:814–8. https://doi.org/10.1002/jmv.25801.Search in Google Scholar
37. Kuppalli, K, Rasmussen, AL. A glimpse into the eye of the COVID-19 cytokine storm. EBioMedicine 2020;55:55. https://doi.org/10.1016/j.ebiom.2020.102789.Search in Google Scholar
38. Sun, X, Wang, T, Cai, D, Hu, Z, Chen, J, Liao, H, et al.. Cytokine storm intervention in the early stages of COVID-19 pneumonia. Cytokine Growth Factor Rev 2020;53:38–42.10.1016/j.cytogfr.2020.04.002Search in Google Scholar
39. Zhou, F, Yu, T, Du, R, Fan, G, Liu, Y, Liu, Z, et al.. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020;395:1054–62. https://doi.org/10.1016/s0140-6736(20)30566-3.Search in Google Scholar
40. Chen, G, Wu, D, Guo, W, Cao, Y, Huang, D, Wang, H, et al.. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest 2020;130:2620–9. https://doi.org/10.1172/JCI137244.Search in Google Scholar PubMed PubMed Central
41. Staedtke, V, Bai, R-Y, Kim, K, Darvas, M, Davila, ML, Riggins, GJ, et al.. Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome. Nature 2018;564:273–7. https://doi.org/10.1038/s41586-018-0774-y.Search in Google Scholar PubMed PubMed Central
42. Vogelstein, JT, Powell, M, Xiong, R, Shen, Z, Fischer, N, Huq, S, et al.. Alpha-1 adrenergic receptor antagonists prevent acute respiratory distress syndrome and death: implications for Coronavirus disease 2019. arXiv preprint arXiv 2004;10117.Search in Google Scholar
43. Tu, W-J, Cao, J, Yu, L, Hu, X, Liu, Q. Clinicolaboratory study of 25 fatal cases of COVID-19 in Wuhan. Intensive Care Med 2020;46:1–4. https://doi.org/10.1007/s00134-020-06023-4.Search in Google Scholar
44. Zhao, M. Cytokine storm and immunomodulatory therapy in COVID-19: role of chloroquine and anti-IL-6 monoclonal antibodies. Int J Antimicrob Agents 2020;55:105–9. https://doi.org/10.1016/j.ijantimicag.2020.105982.Search in Google Scholar
45. Ciavarella, C, Motta, I, Valente, S, Pasquinelli, G. Pharmacological (or synthetic) and nutritional agonists of PPAR-γ as candidates for cytokine storm modulation in COVID-19 disease. Molecules 2020;25:2076. https://doi.org/10.3390/molecules25092076.Search in Google Scholar
46. Konig, MF, Powell, M, Staedtke, V, Bai, RY, Thomas, DL, Fisher, N, et al.. Targeting the catecholamine-cytokine axis to prevent SARS-CoV-2 cytokine storm syndrome. J Clin Invest 2020;130:3345–7.10.1101/2020.04.02.20051565Search in Google Scholar
47. Gritti, G, Raimondi, F, Bottazzi, B, Ripamonti, D, Riva, I, Landi, F, et al.. Siltuximab downregulates interleukin-8 and pentraxin 3 to improve ventilatory status and survival in severe COVID-19. Leukemia 2021;1:1–5.10.1038/s41375-021-01329-8Search in Google Scholar
48. Chaolin, H, Wang, Y, Li, X, Ren, L, Zhao, J, Hu, Y, et al.. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:497–506.10.1016/S0140-6736(20)30183-5Search in Google Scholar
49. Castelnovo, L, Tamburello, A, Lurati, A, Zaccara, E, Marrazza, MG, Olivetti, M, et al.. Anti-IL6 treatment of serious COVID-19 disease: a monocentric retrospective experience. Medicine 2021;100:1–4.10.1097/MD.0000000000023582Search in Google Scholar PubMed PubMed Central
50. Gov, C. Evaluation of the efficacy and safety of sarilumab in hospitalized patients with COVID-19. BMJ Open 2020;10:399–405.Search in Google Scholar
51. Bastiaan, M, Bosteels, C, Leeuw, DE, Declercq, J, Damme, KV, Delporte, A, et al.. Treatment of severely ill COVID-19 patients with anti-interleukin drugs (COV-AID): a structured summary of a study protocol for a randomised controlled trial. BMC Trials 2020;21:1–2.10.1186/s13063-020-04453-5Search in Google Scholar
52. Zhao, H, Zhu, Q, Zhang, C, Li, J, Wei, M, Qin, Y, et al.. Tocilizumab combined with favipiravir in the treatment of COVID-19: a multicenter trial in a small sample size. Biomed Pharmacother 2021;133:110–8.10.1016/j.biopha.2020.110825Search in Google Scholar PubMed PubMed Central
© 2021 Walter de Gruyter GmbH, Berlin/Boston
Articles in the same Issue
- Frontmatter
- Research Articles
- Isolation and characterization of chemical constituents from Chaerophyllum bulbosum roots and their enzyme inhibitory and antioxidant effects
- Monascin and monascinol, azaphilonoid pigments from Mortierella polycephala AM1: in silico and in vitro targeting of the angiogenic VEGFR2 kinase
- Novel Ag(I)-NHC complex: synthesis, in vitro cytotoxic activity, molecular docking, and quantum chemical studies
- NLRP3 inflammasome activation and oxidative stress status in the mild and moderate SARS-CoV-2 infected patients: impact of melatonin as a medicinal supplement
- Oxidative stress and cyto-genotoxicity induced by poly-d-glucosamine in human blood cells in vitro
- A synergy interaction of artocarpin and tetracycline against Pseudomonas aeruginosa and its mechanism of action on membrane permeability
- Review Articles
- Cytokine storm syndrome in SARS-CoV-2: a review
- A comprehensive review on the development of probiotic supplemented confectioneries
Articles in the same Issue
- Frontmatter
- Research Articles
- Isolation and characterization of chemical constituents from Chaerophyllum bulbosum roots and their enzyme inhibitory and antioxidant effects
- Monascin and monascinol, azaphilonoid pigments from Mortierella polycephala AM1: in silico and in vitro targeting of the angiogenic VEGFR2 kinase
- Novel Ag(I)-NHC complex: synthesis, in vitro cytotoxic activity, molecular docking, and quantum chemical studies
- NLRP3 inflammasome activation and oxidative stress status in the mild and moderate SARS-CoV-2 infected patients: impact of melatonin as a medicinal supplement
- Oxidative stress and cyto-genotoxicity induced by poly-d-glucosamine in human blood cells in vitro
- A synergy interaction of artocarpin and tetracycline against Pseudomonas aeruginosa and its mechanism of action on membrane permeability
- Review Articles
- Cytokine storm syndrome in SARS-CoV-2: a review
- A comprehensive review on the development of probiotic supplemented confectioneries
